All In Biotech

Drug Trial Radar · NCT07190196

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

A Randomized, Phase 3, Double-blind, 52-week Study to Evaluate the Efficacy and Safety of Rilzabrutinib (SAR444671) Compared to Placebo in Adult Participants With Active IgG4-related Disease

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

124

Planned (sponsor's estimate)

Start

Sep 26, 2025

Primary completion

Jun 28, 2028

Study completion Dec 25, 2030

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Sep 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and safety of rilzabrutinib as a treatment for adult patients with active IgG4-RD. The purpose of this study is to measure time to adjudicated IgG4-RD clinical disease flare, and other relevant efficacy endpoints including flare-free rate, control of IgG4-RD disease activity, use of GC rescue and safety parameters such as treatment-emergent adverse events, clinical laboratory values and electrocardiograms (ECG) in participants aged 18 years and above, diagnosed with IgG4-RD and treated with rilzabrutinib tablets over a 52-week placebo-controlled period. Study details include: The study duration will be up to 60 weeks, including a Screening period of 4 to 6 weeks, a 52-week double blind treatment period, and 2 weeks of follow up (plus an optional OLE of 108 weeks). The number of visits will be 16 (plus an optional 9 visits during the OLE).

Conditions

  • Immunoglobulin G4 Related Disease

Interventions

  • RilzabrutinibDrug

    Pharmaceutical form:Tablet-Route of administration:Oral

  • PlaceboDrug

    Pharmaceutical form:Tablet-Route of administration:Oral

  • GlucocorticoidDrug

    Pharmaceutical form:Tablet, solution, suspension formulations according to local standard practices-Route of administration:Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first adjudicated clinical disease flare treated by the investigator during the Blinded Treatment periodTime frame: Until Week 52

Locations

95 sites in 19 countries. Site status is shown where the registry gives one.

  • Kaiser Permanente - Fontana Medical Center- Site Number : 8400015

    Fontana, California · Recruiting

  • University of California Davis Health- Site Number : 8400012

    Sacramento, California · Recruiting

  • San Jose Clinical Trials- Site Number : 8400016

    San Jose, California · Recruiting

  • Solace Clinical Research - Tustin- Site Number : 8400020

    Tustin, California · Recruiting

  • Life Clinical Trials - Margate - Colonial Drive- Site Number : 8400002

    Margate, Florida · Recruiting

  • Vitalia Medical Research - Margate- Site Number : 8400025

    Palm Beach Gardens, Florida · Recruiting

  • Tampa General Hospital - Tampa - General Circle- Site Number : 8400027

    Tampa, Florida · Recruiting

  • Emory University School of Medicine - Atlanta- Site Number : 8400013

    Atlanta, Georgia · Recruiting

  • Primeway Clinical Research- Site Number : 8400019

    Fayetteville, Georgia · Recruiting

  • Massachusetts General Hospital- Site Number : 8400008

    Boston, Massachusetts · Recruiting

  • Henry Ford Hospital- Site Number : 8400009

    Detroit, Michigan · Recruiting

  • Mayo Clinic in Rochester - Minnesota- Site Number : 8400017

    Rochester, Minnesota · Recruiting

  • Icahn School of Medicine at Mount Sinai- Site Number : 8400014

    New York, New York · Recruiting

  • Arthritis and Osteoporosis Consultants of the Carolinas- Site Number : 8400035

    Charlotte, North Carolina · Recruiting

  • Cleveland Clinic - Cleveland- Site Number : 8400001

    Cleveland, Ohio · Recruiting

  • Ohio State University Wexner Medical Center- Site Number : 8400024

    Columbus, Ohio · Recruiting

  • Paramount Medical Research and Consulting LLC- Site Number : 8400018

    Middleburg Heights, Ohio · Recruiting

  • Stryde Research- Site Number : 8400011

    Plano, Texas · Recruiting

  • Epic Medical Research - Red Oak- Site Number : 8400003

    Red Oak, Texas · Recruiting

  • Digestive Health Research of North Texas- Site Number : 8400021

    Wichita Falls, Texas · Recruiting

  • Velocity Clinical Research - Seattle- Site Number : 8400005

    Seattle, Washington · Recruiting

  • Investigational Site Number : 0320004

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320006

    Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320005

    Berazategui, Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0320003

    San Isidro, Buenos Aires, Argentina · Recruiting

  • Investigational Site Number : 0560001

    Leuven, Belgium · Recruiting

  • Investigational Site Number : 1240004

    Montreal, Quebec, Canada · Recruiting

  • Investigational Site Number : 1240001

    Sherbrooke, Quebec, Canada · Recruiting

  • Investigational Site Number : 1520005

    Concepción, Biobio, Chile · Recruiting

  • Investigational Site Number : 1520006

    Puente Alto, Reg Metropolitana de Santiago, Chile · Recruiting

  • Centro de estudios G y C-Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, Chile · Recruiting

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile · Recruiting

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, Chile · Recruiting

  • Investigational Site Number : 1560008

    Beijing, China · Recruiting

  • Investigational Site Number : 1560004

    Beijing, China · Recruiting

  • Investigational Site Number : 1560001

    Beijing, China · Recruiting

  • Investigational Site Number : 1560012

    Chengdu, China · Recruiting

  • Investigational Site Number : 1560010

    Hangzhou, China · Recruiting

  • Investigational Site Number : 1560003

    Jiazhuang, China · Recruiting

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.